Pirfenidone exhibits cardioprotective effects by regulating myocardial fibrosis and vascular permeability in pressure-overloaded hearts

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 309, Issue 3, 2015, Pages H512-H522

  Yamagami, Kiyoshi ^a   Oka, Toru ^a,c   Wang, Qi ^a   Ishizu, Takamaru ^a   Lee, Jong Kook ^a,c   Miwa, Keiko ^a   Akazawa, Hiroshi ^b,c   Naito, Atsuhiko T ^b,c   Sakata, Yasushi ^a   Komuro, Issei ^b,c  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Endothelial cells; Fibroblasts; Fibrosis; Heart failure; Tight junction

Indexed keywords

CLAUDIN 5; COLLAGEN; PIRFENIDONE; SERUM ALBUMIN; SYNAPTOPHYSIN; TRANSFORMING GROWTH FACTOR BETA; CARDIOTONIC AGENT; CLDN5 PROTEIN, MOUSE; COLLAGEN TYPE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; PYRIDONE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; HEART FIBROBLAST; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE FIBROSIS; HEART PROTECTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; VASCULAR ENDOTHELIUM; ANIMAL; C57BL MOUSE; CAPILLARY PERMEABILITY; CELL CULTURE; DRUG EFFECTS; FIBROBLAST; FIBROSIS; GENETICS; HEART FAILURE; HEART VENTRICLE; METABOLISM; PATHOLOGY;

ANIMALS; CAPILLARY PERMEABILITY; CARDIOTONIC AGENTS; CELLS, CULTURED; CLAUDIN-5; COLLAGEN TYPE I; ENDOTHELIAL CELLS; FIBROBLASTS; FIBROSIS; HEART FAILURE; HEART VENTRICLES; MICE; MICE, INBRED C57BL; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDONES;

EID: 84938632017     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00137.2015     Document Type: Article

References (36)

1. European Medicines Agency (EMA). European Public Assessment Report (Online). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002154/WC500103073.pdf. [25 February 2015].
2. Ariel A, Timor O. Hanging in the balance: endogenous anti-inflammatory mechanisms in tissue repair and fibrosis. J Pathol 229: 250–263, 2013.
3. Baker AH, Zaltsman AB, George SJ, Newby AC. Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. J Clin Invest 101: 1478–1487, 1998.
4. Choi K, Lee K, Ryu SW, Im M, Kook KH, Choi C. Pirfenidone inhibits transforming growth factor-beta1-induced fibrogenesis by blocking nuclear translocation of Smads in human retinal pigment epithelial cell line ARPE-19. Mol Vis 18: 1010–1020, 2012.
5. Conte E, Gili E, Fagone E, Fruciano M, Iemmolo M, Vancheri C. Effect of pirfenidone on proliferation, TGF-beta-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. Eur J Pharm Sci 58: 13–19, 2014.
6. Curry FR, Noll T. Spotlight on microvascular permeability. Cardiovasc Res 87: 195–197, 2010.
7. Dongaonkar RM, Stewart RH, Geissler HJ, Laine GA. Myocardial microvascular permeability, interstitial oedema, and compromised cardiac function. Cardiovasc Res 87: 331–339, 2010.
8. Fotheringham J, Odudu A, McKane W, Ellam T. Modification of the relationship between blood pressure and renal albumin permeability by impaired excretory function and diabetes. Hypertension 65: 510–516, 2014.
9. Garcia L, Hernandez I, Sandoval A, Salazar A, Garcia J, Vera J, Grijalva G, Muriel P, Margolin S, Armendariz-Borunda J. Pirfenidone effectively reverses experimental liver fibrosis. J Hepatol 37: 797–805, 2002.
10. Ghosh AK, Vaughan DE. PAI-1 in tissue fibrosis. J Cell Physiol 227: 493–507, 2012.
11. Hashmi S, Al-Salam S. Hypoxia-inducible factor-1 alpha in the heart: a double agent? Cardiol Rev 20: 268–273, 2012.
12. Kai H, Kuwahara F, Tokuda K, Imaizumi T. Diastolic dysfunction in hypertensive hearts: roles of perivascular inflammation and reactive myocardial fibrosis. Hypertens Res 28: 483–490, 2005.
13. Kaibori M, Yanagida H, Yokoigawa N, Hijikawa T, Kwon AH, Okumura T, Kamiyama Y. Effects of pirfenidone on endotoxin-induced liver injury after partial hepatectomy in rats. Transplant Proc 36: 1975-1976, 2004.
14. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW; ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370: 2083-2092, 2014.
15. Kuwahara F, Kai H, Tokuda K, Kai M, Takeshita A, Egashira K, Imaizumi T. Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 106: 130–135, 2002.
16. Ma Z, Pan Y, Huang W, Yang Y, Wang Z, Li Q, Zhao Y, Zhang X, Shen Z. Synthesis and biological evaluation of the pirfenidone derivatives as antifibrotic agents. Bioorg Med Chem Lett 24: 220–223, 2014.
17. Mays TA, Binkley PF, Lesinski A, Doshi AA, Quaile MP, Margulies KB, Janssen PM, Rafael-Fortney JA. Claudin-5 levels are reduced in human end-stage cardiomyopathy. J Mol Cell Cardiol 45: 81–87, 2008.
18. Miric G, Dallemagne C, Endre Z, Margolin S, Taylor SM, Brown L. Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. Br J Pharmacol 133: 687–694, 2001.
19. Muraoka N, Yamakawa H, Miyamoto K, Sadahiro T, Umei T, Isomi M, Nakashima H, Akiyama M, Wada R, Inagawa K, Nishiyama T, Kaneda R, Fukuda T, Takeda S, Tohyama S, Hashimoto H, Kawamura Y, Goshima N, Aeba R, Yamagishi H, Fukuda K, Ieda M. MiR-133 promotes cardiac reprogramming by directly repressing Snai1 and silencing fibroblast signatures. EMBO J 33: 1565–1581, 2014.
20. Nguyen DT, Ding C, Wilson E, Marcus GM, Olgin JE. Pirfenidone mitigates left ventricular fibrosis and dysfunction after myocardial infarction and reduces arrhythmias. Heart Rhythm 7: 1438–1445, 2010.
21. Nitta T, Hata M, Gotoh S, Seo Y, Sasaki H, Hashimoto N, Furuse M, Tsukita S. Size-selective loosening of the blood-brain barrier in claudin- 5-deficient mice. J Cell Biol 161: 653–660, 2003.
22. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM; CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377: 1760–1769, 2011.
23. Oka T, Maillet M, Watt AJ, Schwartz RJ, Aronow BJ, Duncan SA, Molkentin JD. Cardiac-specific deletion of Gata4 reveals its requirement for hypertrophy, compensation, and myocyte viability. Circ Res 98: 837–845, 2006.
24. Oku H, Shimizu T, Kawabata T, Nagira M, Hikita I, Ueyama A, Matsushima S, Torii M, Arimura A. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol 590: 400–408, 2008.
25. Persidsky Y, Heilman D, Haorah J, Zelivyanskaya M, Persidsky R, Weber GA, Shimokawa H, Kaibuchi K, Ikezu T. Rho-mediated regulation of tight junctions during monocyte migration across the blood-brain barrier in HIV-1 encephalitis (HIVE). Blood 107: 4770–4780, 2006.
26. Schaefer CJ, Ruhrmund DW, Pan L, Seiwert SD, Kossen K. Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev 20: 85–97, 2011.
27. Schultz Jel J, Witt SA, Glascock BJ, Nieman ML, Reiser PJ, Nix SL, Kimball TR, Doetschman T. TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest 109: 787–796, 2002.
28. Sirotkin H, Morrow B, Saint-Jore B, Puech A, Das Gupta R, Patanjali SR, Skoultchi A, Weissman SM, Kucherlapati R. Identification, characterization, and precise mapping of a human gene encoding a novel membrane-spanning protein from the 22q11 region deleted in velo-cardiofacial syndrome. Genomics 42: 245–251, 1997.
29. Swager SA, Delfin DA, Rastogi N, Wang H, Canan BD, Fedorov VV, Mohler PJ, Kilic A, Higgins RS, Ziolo MT, Janssen PM, Rafael- Fortney JA. Claudin-5 levels are reduced from multiple cell types in human failing hearts and are associated with mislocalization of ephrin-B 1. Cardiovasc Pathol 24: 160–167, 2014.
30. Takakura K, Mizukami K, Mitori H, Noto T, Tomura Y. Antiproteinuric effect of pirfenidone in a rat model of anti-glomerular basement membrane glomerulonephritis. Eur J Pharmacol 737: 106–116, 2014.
31. Tsukita S, Furuse M, Itoh M. Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol 2: 285–293, 2001.
32. Ueda K, Takano H, Niitsuma Y, Hasegawa H, Uchiyama R, Oka T, Miyazaki M, Nakaya H, Komuro I. Sonic hedgehog is a critical mediator of erythropoietin-induced cardiac protection in mice. J Clin Invest 120: 2016–2029, 2010.
33. Wang Y, Wu Y, Chen J, Zhao S, Li H. Pirfenidone attenuates cardiac fibrosis in a mouse model of TAC-induced left ventricular remodeling by suppressing NLRP3 inflammasome formation. Cardiology 126: 1–11, 2013.
34. Waters CM. Flow-induced modulation of the permeability of endothelial cells cultured on microcarrier beads. J Cell Physiol 168: 403–411, 1996.
35. Wilkins BJ, Dai YS, Bueno OF, Parsons SA, Xu J, Plank DM, Jones F, Kimball TR, Molkentin JD. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res 94: 110–118, 2004.
36. Yamazaki T, Yamashita N, Izumi Y, Nakamura Y, Shiota M, Hanatani A, Shimada K, Muro T, Iwao H, Yoshiyama M. The antifibrotic agent pirfenidone inhibits angiotensin II-induced cardiac hypertrophy in mice. Hypertens Res 35: 34–40, 2012.